Daratumumab-based regimen for newly diagnosed multiple myeloma patients with paraskeletal plasmacytomas: a retrospective study in a single center

To analyze the efficacy of daratumumab-based regimen in newly diagnosed multiple myeloma(NDMM) patients with paraskeletal plasmacytomas (PPs). The medical data of 28 NDMM patients with PPs were retrospectively analyzed. The daratumumab-based regimen was divided into group A, and the daratumumab-free...

Full description

Saved in:
Bibliographic Details
Published in:Hematology (Luxembourg) Vol. 29; no. 1; p. 2431958
Main Authors: Xu, Shuiqing, Chen, Wenming, Li, Yanchen
Format: Journal Article
Language:English
Published: England Taylor & Francis Group 01.12.2024
Subjects:
Adult
Aged
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
daratumumab-based
daratumumab-free
Female
Humans
Male
Middle Aged
Multiple myeloma
Multiple Myeloma - drug therapy
Multiple Myeloma - mortality
newly-diagnosed
paraskeletal plasmacytomas
Plasmacytoma - diagnosis
Plasmacytoma - drug therapy
Plasmacytoma - mortality
Retrospective Studies
risk factors
risk factors
Multiple myeloma
overall survival
daratumumab-free
newly-diagnosed
daratumumab-based
paraskeletal plasmacytomas
efficacy
ISSN:1607-8454, 1607-8454
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To analyze the efficacy of daratumumab-based regimen in newly diagnosed multiple myeloma(NDMM) patients with paraskeletal plasmacytomas (PPs). The medical data of 28 NDMM patients with PPs were retrospectively analyzed. The daratumumab-based regimen was divided into group A, and the daratumumab-free regimen was divided into group B. The risk factors, efficacy, and overall survival (OS) were compared between the two groups. The results of univariate COX regression analysis showed that only the grouping and creatinine were statistically significant. The HR value of group A was 0.30(0.10-0.88,  = 0.029), which was a protective factor for patient survival, and the HR value of creatinine was 1.00(1.00-1.01,  = 0.026), which was a risk factor for patient survival. There was a statistically significant difference in efficacy between the two groups,  = 0.025 < 0.05. The results showed that the efficacy of group A was better. There was a statistically significant difference in OS between the two groups (54:27,  = 0.002). The results indicated that the treatment regimens containing daratumumab could prolong the OS of patients, suggesting that for MM patients with extramedullary disease(EMD), daratumumab-based combination treatment regimens can be given priority.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1607-8454
1607-8454
DOI:10.1080/16078454.2024.2431958